CMMB
Income statement / Annual
Last year (2025), Chemomab Therapeutics Ltd's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Chemomab Therapeutics Ltd's net income was -$9.00 M.
See Chemomab Therapeutics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$66.83 K
|
$57.77 K
|
$34.02 K
|
$80.56 K
|
$281.91 K
|
$66.00 K
|
$51.00 K
|
$40.64 K
|
| Gross Profit |
$0.00
|
$0.00
|
-$66.83 K
|
-$57.77 K
|
-$34.02 K
|
-$80.56 K
|
-$282.00 K
|
-$65.79 K
|
-$51.00 K
|
-$40.64 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.83 M
|
$11.33 M
|
$18.38 M
|
$16.98 M
|
$6.30 M
|
$3.81 M
|
$13.35 M
|
$7.51 M
|
$6.23 M
|
$2.34 M
|
| General & Administrative Expenses |
$3.73 M
|
$3.41 M
|
$7.08 M
|
$11.56 M
|
$0.00
|
$0.00
|
$6.25 M
|
$5.49 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.73 M
|
$3.41 M
|
$7.08 M
|
$11.56 M
|
$6.04 M
|
$7.15 M
|
$5.98 M
|
$5.46 M
|
$3.11 M
|
$2.25 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$9.57 M
|
$14.74 M
|
$25.46 M
|
$28.53 M
|
$12.34 M
|
$10.96 M
|
$19.33 M
|
$12.97 M
|
$9.34 M
|
$4.59 M
|
| Cost And Expenses |
$9.57 M
|
$14.74 M
|
$25.46 M
|
$28.53 M
|
$12.38 M
|
$11.04 M
|
$19.61 M
|
$13.04 M
|
$9.39 M
|
$4.63 M
|
| Interest Income |
$572.00 K
|
$794.00 K
|
$1.24 M
|
$351.62 K
|
$0.00
|
$20.14 K
|
$393.00 K
|
$0.00
|
$1.00 K
|
$521.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$353.00 K
|
$111.08 K
|
$6.04 K
|
$9.00 K
|
$0.00
|
$5.00 K
|
$0.00
|
| Depreciation & Amortization |
$70.00 K
|
$53.00 K
|
$67.00 K
|
$57.77 K
|
$34.02 K
|
$80.56 K
|
$281.91 K
|
$65.79 K
|
$51.40 K
|
$40.78 K
|
| EBITDA |
-$9.50 M |
-$14.69 M |
-$25.39 M |
-$28.48 M |
-$12.34 M |
-$10.96 M |
-$26.92 M |
-$13.36 M |
-$9.50 M |
-$4.57 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$572.00 K
|
$794.00 K
|
$1.24 M
|
$353.00 K
|
-$111.08 K
|
-$650.53 K
|
-$7.60 M
|
-$456.00 K
|
-$91.71 K
|
$36.33 K
|
| Income Before Tax |
-$9.00 M
|
-$13.95 M
|
-$24.22 M
|
-$28.18 M
|
-$12.49 M
|
-$11.69 M
|
-$27.21 M
|
-$5.87 M
|
-$9.56 M
|
-$4.61 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$534.00 K
|
$0.00
|
$0.00
|
$0.00
|
$306.00 K
|
$323.00 K
|
$136.24 K
|
| Net Income |
-$9.00 M
|
-$13.95 M
|
-$24.22 M
|
-$27.65 M
|
-$12.49 M
|
-$11.69 M
|
-$27.21 M
|
-$13.80 M
|
-$9.81 M
|
-$4.73 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.42 |
-68.8 |
-8.22 |
-9.68 |
-4.8 |
-504.2 |
-63.2 |
-87.09 |
-875.98 |
-69 |
| EPS Diluted |
-1.42 |
-68.8 |
-8.22 |
-9.68 |
-4.8 |
-504.2 |
-63.2 |
-87.09 |
-875.98 |
-69 |
| Weighted Average Shares Out |
$6.38 M
|
$202.91 K
|
$2.94 M
|
$2.84 M
|
$2.59 M
|
$23.19 K
|
$430.58 K
|
$157.93 K
|
$11.28 K
|
$67.92 K
|
| Weighted Average Shares Out Diluted |
$6.38 M
|
$202.91 K
|
$2.94 M
|
$2.84 M
|
$2.59 M
|
$23.19 K
|
$430.58 K
|
$157.93 K
|
$11.28 K
|
$67.92 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
